The New Neglected Diseases?
Policy Interventions Are Needed to Encourage CNS Drug Development
Download Free Electronic Document
| Format | File Size | Notes |
|---|---|---|
| PDF file | 0.2 MB | Use Adobe Acrobat Reader version 10 or higher for the best experience. |
This paper evaluates the causes of the unmet need for investment in drugs targeting central nervous system diseases and discusses policy solutions to better align drug development with untreated disease burden. The authors' analysis suggests that current market forces are stacking the deck against development of drugs for common CNS disorders, as the expected returns on investment are lower and more uncertain than those for, say, targeted cancer drugs. They propose several policy changes that could steer investment into drugs for these "new neglected diseases" by reducing development cost and uncertainty and increasing expected revenue.
The research underlying this paper was conducted in RAND Health, a division of the RAND Corporation.
This commentary is part of the RAND Corporation Expert insight series. RAND Expert Insights present perspectives on timely policy issues. All RAND Expert Insights undergo peer review to ensure high standards for quality and objectivity.
This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.